UK company announcements filtered and explained for private investors.
Bytes Technology Group plc (BYIT) · 2026-09-17
Bytes Technology traded ahead of expectations in the first half of FY27 and upgraded full-year guidance. The Board now expects Gross Profit growth in the low to mid-teens and Operating Profit growth in the low to mid single-digits, despite higher technology and bonus costs.
Galliford Try Holdings plc (GFRD) · 2026-09-17
Galliford Try's adjusted profit before tax rose 24.2% to £55.9m as revenue increased 3.0% to £1,931.1m, with profit above market expectations. The group also announced a further £15m share buyback.
AB Dynamics plc (ABDP) · 2026-09-17
AB Dynamics expects FY2026 revenue from continuing operations of £91.6m and an adjusted operating margin in line with its 20% medium-term target, matching guidance and market expectations. A £31m year-end order book provides coverage into the first half of FY2027.
Billington Holdings Plc (BILN) · 2026-09-17
Billington has won two data centre contracts worth circa £42 million, adding significantly to a record order book and extending delivery activity through 2028.
FRASERS GROUP PLC (FRAS) · 2026-09-17
Frasers Group has arranged a share buyback programme allowing purchases of up to 10,000,000 ordinary shares, with aggregate spending capped at £80,000,000. The stated purpose is to reduce share capital, with acquired shares placed into treasury.
Fadel Partners, Inc. (FADL) · 2026-09-17
Fadel Partners narrowed its adjusted EBITDA loss by 53% to $1.1 million in the first half of 2026 as revenue grew 4% to $4.8 million. Higher-margin licence and support revenue helped lift gross margin from 49% to 61%.
Unicorn Mineral Resources Plc (UMR) · 2026-09-17
Unicorn Mineral Resources has drawn its full £1.25 million unsecured loan facility, adding working capital to progress the Klein Aub Copper Mine acquisition in Namibia and initial development plans. The funding comes from a company controlled by chairman Paddy Doherty.
Galliford Try Holdings plc (GFRD) · 2026-09-17
Galliford Try intends to launch a share buyback of up to £15 million, returning funds to shareholders who sell and reducing share capital through cancellation of purchased shares. The programme is subject to market conditions and is intended to complete by 30 June 2027.
Helios Towers plc (HTWS) · 2026-09-17
Helios Towers has expanded its share buyback programme by up to US$100 million, taking its total size from US$75 million to US$175 million. The programme is expected to run until 31 December 2027, with all repurchased ordinary shares cancelled.
The Beauty Tech Group plc (TBTG) · 2026-09-17
The Beauty Tech Group intends to launch an up to £20 million share buyback within four weeks, with repurchased shares expected to be cancelled to reduce share capital. The proposed return follows net cash of approximately £52.0 million at 30 June 2026.
Landore Resources Limited (LND) · 2026-09-17
Landore Resources Limited's six-month loss narrowed to £587,755 from £1,282,031, while cash and cash equivalents stood at £991,953 at 30 June 2026. The directors consider the group adequately funded for the foreseeable future, based on its cash position and ability to raise capital.
OptiBiotix Health plc (OPTI) · 2026-09-17
OptiBiotix Health's cash fell to £0.99m from £1.30m despite a debt-free balance sheet, while India sales fell to £3k from £114k. Gross profit increased 25.4% to £380k as cost-of-goods changes began to take effect.
Anglesey Mining plc (AYM) · 2026-09-17
Anglesey Mining swung to a £2.08 million profit after tax from a £0.66 million loss, principally on a £2.92 million restructuring gain. Group loans fell to £110,000 from £4.05 million, but the exploration-stage Group has no operating revenues.
CEPS's operating profit fell to £35,000 in H1 2026 from £1.354m as sales dropped to £8.998m from £16.817m, partly reflecting reduced ICA Group inclusion. The ICA Group sale generated £12.347m net cash consideration, leaving £9.742m cash and no external debt.
EDX Medical Group plc (EDX) · 2026-09-17
EDX Medical has signed an initial three-year employee health screening agreement with Arnold Clark Group, expected to generate annual revenues of between £1.4 and £1.6million. The forecast assumes high participation from eligible employees.
MISSION Group plc (TMG) · 2026-09-17
MISSION has completed the final stages of simplifying its agency portfolio, combining Mongoose with Bray Leino Events and integrating Bray Leino with krow Group. The Mongoose business will deliver over 250 experiences annually across more than 30 countries.
EnergyPathways PLC (EPP) · 2026-09-17
EnergyPathways has signed an agreement with Finland's Hycamite TCD Technologies to evaluate technology for its planned hydrogen plant. Company scoping indicates potential annual revenue of £90 million - £120 million, but technology selection depends on government support and future offtake value.
Savannah Resources Plc (SAV) · 2026-09-17
Savannah Resources' construction-related field programme at Barroso is nearing completion, with access and groundwork finished and 189 geotechnical pits logged. Hydrogeological drilling has reached 696m of 800m planned, while the programme is expected to finish in coming weeks ahead of the Portuguese State authorisation period.
ECO Animal Health Group plc (EAH) · 2026-09-17
ECOVAXXIN® MS has secured approval for its US field safety data following a trial in more than 170,000 commercial laying pullets. US marketing approval is expected by the end of the calendar year, advancing the vaccine towards launch.
Manx Financial Group PLC (MFX) · 2026-09-17
Manx Financial has begun merging three UK finance subsidiaries under the Triskel Finance brand, targeting Triskel Finance profit before tax of £1.1 million in 2028, up £1.0 million from £0.1 million in 2025.
SysGroup plc (SYS) · 2026-09-17
SysGroup's trading has maintained the Q4 FY26 exit run rate, with sales growth and margins holding consistently. The group also secured its first UK public-sector contract through the G-Cloud 15 framework and expects full-year results in line with market expectations.
Atome Energy PLC (ATOM) · 2026-09-17
Atome Energy will serve notice of an intended arbitration claim against Paraguay over revoked decrees supporting its US$665 million Villeta Project, removing certainty on the power purchase agreement's term and price. Discussions on the shovel-ready project continue.
GreenRoc Strategic Materials Plc (GROC) · 2026-09-17
GreenRoc's initial assessment puts Amitsoq graphite's climate impact at 1.60 kg CO₂e per kg of CSPG, with downstream processing accounting for approximately 87% and offering reduction potential.
Tertiary Minerals plc (TYM) · 2026-09-17
Tertiary Minerals' Mushima North drilling returned its highest-grade silver-copper intersection, 82m at 89 g/t silver and 0.20% copper, supporting mineralisation beyond the current Exploration Target boundary.
CRISM Therapeutics Corporation (CRTX) · 2026-09-17
CRISM Therapeutics will appoint Dr Charles Spicer as Non-Executive Chair from 1 October 2026, allowing Andrew Webb to resume solely as Chief Executive Officer. The governance change comes as Phase 2 patient recruitment for irinotecan-ChemoSeed in glioblastoma is under way.
Alkemy Capital Investments plc (ALK) · 2026-09-17
Alkemy's Tees Valley Lithium has received an in-principle offer of up to £18.3 million in non-dilutive UK government grant funding for its £185 million Phase 1 refinery, strengthening financing. The support remains conditional on final approvals, due diligence and other conditions.
Serval Resources Plc (SRVL) · 2026-09-17
Serval has completed geophysics at Somelo and is nearing completion at Sweet Thorn Pan, with integrated interpretation and follow-up targets expected by end-October 2026. Any follow-up exploration, including drilling, remains subject to additional funding.
RWS Holdings plc (RWS) · 2026-09-17
Patrick De Smedt will become RWS's independent Non-Executive Director and Chair on 8 October 2026, replacing interim Chair Andrew Brode. De Smedt will also chair the Nomination Committee, while Brode remains a Non-Executive Director.
ICG completed its approximately £274 million buyback, repurchasing 15,280,825 Ordinary Shares under a programme designed to support a non-dilutive Amundi share issuance. Amundi now has a 9.9% economic interest, including 4.9% voting interest.